Linear Clinical Research | Perth, Australia
Status and phase
Conditions
Treatments
About
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Ability to understand and be willing to sign an informed consent form
Exclusion criteria
Prior treatment with HMBD-001, pertuzumab, or an agent that specifically targets HER3, including pan-HER tyrosine kinase inhibitors
Primary purpose
Allocation
Interventional model
Masking
68 participants in 4 patient groups
Loading...
Central trial contact
Kon Yew Kwek, BMBCh, DPhil
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal